Loading stock…

PROCEPT BioRobotics Corporation (PRCT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

PROCEPT BioRobotics Corporation

PRCTMarket cap $1.00BPrice $17.5

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes robotic systems that treat enlarged prostates by vaporizing tissue with a precise waterjet, sparing nerves that scalpels can't avoid. Surgeons across the U.S. increasingly choose this over decades-old procedures for faster recovery and fewer side effects.

In Bastion Portfolios?

52W Return-47%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+60%10

Revenue Forecast

Rev CAGR (1y)+28%9

Rev CAGR (3y)+22%9

Rev CAGR (5y)+18%9

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-35%1

Net Income Margin-33%1

Free Cash Flow Margin-25%2

Debt

Net Debt/EBITDAna–

Efficiency

ROE-30%1

ROA-22%1

Earnings Stabilityna–

GEAR+VERY WEAK8

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2.95

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-8.5%1

Dividend Yieldna–

Momentum

Short term

1 month return-23%1

3 month return-17%2

YTD return-44%1

Mid term

Price vs 52wHigh46%1

1 year return-49%1

Long term

3 year return-44%1

5 year return-55%1

Risk Shield

Price Risk

Beta0.76

Volatility64%2

Free Cash Flow

Free Cash Flow Margin-25%2

Free Cash Flow Yield-8.5%1

Quality

ROCE-27%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

PRCTPROCEPT BioRobotics

Revenue FY25$308M

GROWTH RATING↗

STRONG79 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+60%10

Revenue, next 1Y+28%9

Revenue, next 3Y, CAGR+22%9

Revenue, next 5Y, CAGR+18%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 79% of companies worldwide.

Revenue grew 60%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 22%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 18%/yr over five years.9/10

WATCH

Revenue grew 60%/yr over the last 3 years; forecasts see it cooling to 22%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-23%1

3-month return-17%2

YTD return-44%1

MID & LONG-TERM▾SCORE

% of 52-week high46%1

1-year return-49%1

3-year return-44%1

5-year return-55%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-44% over three years and -55% over five), behind 90% of the market.

It's down 49% over the past year, now 54% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-23%), over three months (-17%) and so far this year (-44%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on PROCEPT BioRobotics Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PRCTPROCEPT BioRobotics

Revenue FY25$308M

GROWTH RATING↗

STRONG79 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+60%10

Revenue, next 1Y+28%9

Revenue, next 3Y, CAGR+22%9

Revenue, next 5Y, CAGR+18%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 79% of companies worldwide.

Revenue grew 60%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 22%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 18%/yr over five years.9/10

WATCH

Revenue grew 60%/yr over the last 3 years; forecasts see it cooling to 22%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-23%1

3-month return-17%2

YTD return-44%1

MID & LONG-TERM▾SCORE

% of 52-week high46%1

1-year return-49%1

3-year return-44%1

5-year return-55%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-44% over three years and -55% over five), behind 90% of the market.

It's down 49% over the past year, now 54% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-23%), over three months (-17%) and so far this year (-44%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on PROCEPT BioRobotics Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community